Invasive Klebsiella pneumoniae liver abscess syndrome complicated by carbapenem-resistant Acinetobacter baumannii infection: a case report

Front Med (Lausanne). 2025 Jan 7:11:1511734. doi: 10.3389/fmed.2024.1511734. eCollection 2024.

Abstract

Background: A liver abscess caused by hypervirulent Klebsiella pneumoniae can lead to multiple invasive extrahepatic infections, including lung abscesses, endophthalmitis, brain abscesses, and necrotizing fasciitis. This condition, known as Klebsiella pneumoniae liver abscess invasion syndrome, progresses rapidly and is associated with severe illness, high disability rates, and significant mortality. However, bloodstream infections with co-infection involving carbapenem-resistant Acinetobacter baumannii are exceedingly rare.

Case presentation: The Emergency Medicine Department of the First People's Hospital of Kunshan successfully treated a male patient diagnosed with liver, lung, and prostate abscesses. The patient underwent puncture and drainage, with analysis of the drainage fluid, sputum culture, and metagenomic next-generation sequencing (m-NGS) revealing a co-infection with blood-borne Klebsiella pneumoniae and Acinetobacter baumannii. Guided by drug sensitivity test results, the patient received treatment with polymyxin and cefoperazone sodium-sulbactam sodium for infection control and liver protection. The treatment was successful, and the patient fully recovered and was discharged.

Conclusion: By reporting this rare case and highlighting the drug resistance of the bacteria, we propose a new diagnosis and treatment plan for managing Klebsiella pneumoniae combined with carbapenem-resistant Acinetobacter baumannii infection, along with a literature review.

Keywords: Acinetobacter baumannii; Klebsiella pneumoniae; case report; liver abscess invasion syndrome; therapy.

Publication types

  • Case Reports

Grants and funding

The author(s) declare that financial support was received for the research, authorship, and/or publication of this article. This project is supported by Clinical Science and Technology Development Fund of Jiangsu University (No. JLY2021061).